Literature DB >> 20011561

Accomplishments in 2008 in the treatment of advanced metastatic colorectal cancer.

Richard M Goldberg1, Neal J Meropol, Josep Tabernero.   

Abstract

Overview of the Disease IncidencePredictive BiomarkersCurrent General Therapy StandardsAccomplishments During the Year Combined Modality Management of Liver MetastasesTreatment of Advanced Disease Equivalence of FOLFOX and CAPOXAddition of Bevacizumab to Standard ChemotherapyDual EGFR and VEGF InhibitionBevacizumab Upon Progression While on First-Line TherapyBenefit in the Elderly PopulationWhat Needs to be Done Comments on ResearchObstacles to Progress.

Entities:  

Year:  2009        PMID： 20011561      PMCID： PMC2791393     

Source DB:  PubMed          Journal:  Gastrointest Cancer Res        ISSN： 1934-7820


  32 in total

Review 1.  Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer.

Authors:  Helena Linardou; Issa J Dahabreh; Dimitra Kanaloupiti; Fotios Siannis; Dimitrios Bafaloukos; Paris Kosmidis; Christos A Papadimitriou; Samuel Murray
Journal:  Lancet Oncol       Date:  2008-09-17       Impact factor: 41.316

2.  Pharmacogenetic profiling for cetuximab plus irinotecan therapy in patients with refractory advanced colorectal cancer.

Authors:  Francesco Graziano; Annamaria Ruzzo; Fotios Loupakis; Emanuele Canestrari; Daniele Santini; Vincenzo Catalano; Renato Bisonni; Umberto Torresi; Irene Floriani; Gaia Schiavon; Francesca Andreoni; Paolo Maltese; Eliana Rulli; Bostjan Humar; Alfredo Falcone; Lucio Giustini; Giuseppe Tonini; Andrea Fontana; Gianluca Masi; Mauro Magnani
Journal:  J Clin Oncol       Date:  2008-03-20       Impact factor: 44.544

3.  Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer.

Authors:  Jim Cassidy; Stephen Clarke; Eduardo Díaz-Rubio; Werner Scheithauer; Arie Figer; Ralph Wong; Sheryl Koski; Mikhail Lichinitser; Tsai-Shen Yang; Fernando Rivera; Felix Couture; Florin Sirzén; Leonard Saltz
Journal:  J Clin Oncol       Date:  2008-04-20       Impact factor: 44.544

4.  Pharmacogenetic approach for capecitabine or 5-fluorouracil selection to be combined with oxaliplatin as first-line chemotherapy in advanced colorectal cancer.

Authors:  Eva Martinez-Balibrea; Albert Abad; Enrique Aranda; Javier Sastre; Jose Luis Manzano; Eduardo Díaz-Rubio; Auxiliadora Gómez-España; Jorge Aparicio; Teresa García; Inmaculada Maestu; Anna Martínez-Cardús; Alba Ginés; Elisabet Guino
Journal:  Eur J Cancer       Date:  2008-04-28       Impact factor: 9.162

5.  Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer.

Authors:  Steven J Cohen; Cornelis J A Punt; Nicholas Iannotti; Bruce H Saidman; Kert D Sabbath; Nashat Y Gabrail; Joel Picus; Michael Morse; Edith Mitchell; M Craig Miller; Gerald V Doyle; Henk Tissing; Leon W M M Terstappen; Neal J Meropol
Journal:  J Clin Oncol       Date:  2008-07-01       Impact factor: 44.544

6.  Efficacy of oxaliplatin plus capecitabine or infusional fluorouracil/leucovorin in patients with metastatic colorectal cancer: a pooled analysis of randomized trials.

Authors:  Hendrik-Tobias Arkenau; Dirk Arnold; Jim Cassidy; Eduardo Diaz-Rubio; Jean-Yves Douillard; Howard Hochster; Andrea Martoni; Axel Grothey; Axel Hinke; Wolff Schmiegel; Hans-Joachim Schmoll; Rainer Porschen
Journal:  J Clin Oncol       Date:  2008-11-17       Impact factor: 44.544

7.  A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer.

Authors:  J Randolph Hecht; Edith Mitchell; Tarek Chidiac; Carroll Scroggin; Christopher Hagenstad; David Spigel; John Marshall; Allen Cohn; David McCollum; Philip Stella; Robert Deeter; Seta Shahin; Rafael G Amado
Journal:  J Clin Oncol       Date:  2008-12-29       Impact factor: 44.544

8.  Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer.

Authors:  Rafael G Amado; Michael Wolf; Marc Peeters; Eric Van Cutsem; Salvatore Siena; Daniel J Freeman; Todd Juan; Robert Sikorski; Sid Suggs; Robert Radinsky; Scott D Patterson; David D Chang
Journal:  J Clin Oncol       Date:  2008-03-03       Impact factor: 44.544

9.  Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.

Authors:  Federica Di Nicolantonio; Miriam Martini; Francesca Molinari; Andrea Sartore-Bianchi; Sabrina Arena; Piercarlo Saletti; Sara De Dosso; Luca Mazzucchelli; Milo Frattini; Salvatore Siena; Alberto Bardelli
Journal:  J Clin Oncol       Date:  2008-11-10       Impact factor: 44.544

10.  Potential value of PTEN in predicting cetuximab response in colorectal cancer: an exploratory study.

Authors:  Evangelia Razis; Evangelos Briasoulis; Eleni Vrettou; Dimosthenis V Skarlos; Dimitrios Papamichael; Ioannis Kostopoulos; Epaminontas Samantas; Ioannis Xanthakis; Mattheos Bobos; Eleni Galanidi; Maria Bai; Ioanna Gikonti; Alona Koukouma; Georgia Kafiri; Pavlos Papakostas; Konstantine T Kalogeras; Paris Kosmidis; George Fountzilas
Journal:  BMC Cancer       Date:  2008-08-13       Impact factor: 4.430
View more
  1 in total

1.  Accomplishments in 2008 in the management of curable metastatic colorectal cancer.

Authors:  René Adam; Emir Hoti; Gunnar Folprecht; Al B Benson
Journal:  Gastrointest Cancer Res       Date:  2009-09
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.